USANA Health Sciences, Inc. (NYSE:USNA) insider Daniel A. Macuga sold 11,992 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $59.00, for a total value of $707,528.00. Following the completion of the sale, the insider now directly owns 11,992 shares of the company’s stock, valued at approximately $707,528. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of USANA Health Sciences, Inc. (USNA) traded up 0.68% during midday trading on Wednesday, hitting $59.45. The company had a trading volume of 188,508 shares. The firm’s 50-day moving average is $59.52 and its 200-day moving average is $60.19. The firm has a market capitalization of $1.45 billion, a P/E ratio of 15.44 and a beta of 1.10. USANA Health Sciences, Inc. has a 12-month low of $52.55 and a 12-month high of $75.00.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $0.98 EPS for the quarter, missing the consensus estimate of $1.06 by $0.08. The company had revenue of $257.10 million during the quarter, compared to analysts’ expectations of $273.61 million. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The business’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the company earned $2.07 earnings per share. On average, analysts predict that USANA Health Sciences, Inc. will post $3.79 earnings per share for the current fiscal year.

USANA Health Sciences announced that its Board of Directors has approved a stock repurchase program on Tuesday, July 25th that authorizes the company to repurchase $64.60 million in shares. This repurchase authorization authorizes the company to purchase up to 46% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/30/usana-health-sciences-inc-usna-insider-daniel-a-macuga-sells-11992-shares.html.

Several equities research analysts recently commented on the company. BidaskClub cut USANA Health Sciences from a “sell” rating to a “strong sell” rating in a research note on Monday, July 31st. Pivotal Research raised USANA Health Sciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $55.00 to $75.00 in a research note on Wednesday, May 3rd.

Hedge funds have recently modified their holdings of the company. USA Financial Portformulas Corp bought a new stake in shares of USANA Health Sciences during the second quarter valued at approximately $691,000. Phocas Financial Corp. increased its stake in shares of USANA Health Sciences by 4.7% in the second quarter. Phocas Financial Corp. now owns 125,090 shares of the company’s stock valued at $8,018,000 after buying an additional 5,575 shares during the period. California State Teachers Retirement System increased its stake in shares of USANA Health Sciences by 0.5% in the second quarter. California State Teachers Retirement System now owns 20,582 shares of the company’s stock valued at $1,319,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of USANA Health Sciences by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 9,137 shares of the company’s stock valued at $586,000 after buying an additional 616 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of USANA Health Sciences by 711.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 91,409 shares of the company’s stock valued at $5,859,000 after buying an additional 80,145 shares during the period. 44.73% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.